AbbVie (ABBV) Stock May Be A Bargain Following Raised Outlook

Simply Wall St.11-11 23:26

AbbVie has delivered a powerful run, with the stock up 201.5% over the past 5 years and recent news flow focused on new therapies, acquisitions and higher shareholder payouts. With that kind of share ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2682832095?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/company-cover/141885706-card/1789002767761","is_english":true,"pubTime":"2026-11-11 23:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2682832095","market":"hk","top_or_hot":-1,"title":"AbbVie (ABBV) Stock May Be A Bargain Following Raised Outlook","media":"Simply Wall St.","content":"<div>\n<p>AbbVie has delivered a powerful run, with the stock up 201.5% over the past 5 years and recent news flow focused on new therapies, acquisitions and higher shareholder payouts. With that kind of share ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/abbvie-abbv-stock-may-be-a-bargain-following-raised-outlook\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AbbVie (ABBV) Stock May Be A Bargain Following Raised Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbbVie (ABBV) Stock May Be A Bargain Following Raised Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-11-11 23:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/abbvie-abbv-stock-may-be-a-bargain-following-raised-outlook><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AbbVie has delivered a powerful run, with the stock up 201.5% over the past 5 years and recent news flow focused on new therapies, acquisitions and higher shareholder payouts. With that kind of share ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/abbvie-abbv-stock-may-be-a-bargain-following-raised-outlook\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JDOC","symbol_name":"JPMORGAN HEALTHCARE LEADERS ETF","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/abbvie-abbv-stock-may-be-a-bargain-following-raised-outlook","article_id":"2682832095","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/company-cover/141885706-card/1789002767761"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-abbv/abbvie/news/abbvie-abbv-stock-may-be-a-bargain-following-raised-outlook","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2682832095","pubTimestamp":1794410777,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"SSasha JovanovicNovember 11, 2026","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"JDOC":"JPMORGAN HEALTHCARE LEADERS ETF","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","LU2125909247.SGD":"Natixis Thematics Meta H-R/A SGD","IE000WAW04H5.SGD":"RQI GLOBAL \"I\" (SGD) INC A","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","FTXH":"First Trust Nasdaq Pharmaceuticals ETF","LU0553294199.USD":"BGF GLOBAL EQUITY INCOME \"A5G\" (USD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","BK4566":"资本集团","IE000BZT7R73.USD":"RQI GLOBAL \"I\" (USD) ACC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","LU0545039389.USD":"BGF GLOBAL EQUITY INCOME \"A2\" ACC","LU0726765562.USD":"JPM GLOBAL INCOME \"A\" (USD HEDGED) INC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU2129689605.HKD":"FRANKLIN GLOBAL INCOME \"A\" (HKD) INC","LU0689626769.HKD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (HKD) ACC","SG9999015978.USD":"利安颠覆性创新基金A","BK4559":"巴菲特持仓","GLAM":"Corgi Beauty, Skincare & Aesthetics ETF","IXJ":"全球医疗业ETF-iShares","LU0882574055.USD":"富达全球健康医疗A ACC","VHT":"Vanguard Health Care ETF","BK4588":"碎股","FHLC":"Fidelity MSCI Health Care Index","AGNG":"Global X Aging Population ETF","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","SPHQ":"Invesco S&P 500 Quality ETF","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","ABBV":"艾伯维公司","PPH":"VanEck Pharmaceutical ETF","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC","LU1236620834.HKD":"HSBC GIF GLOBAL SUSTAINABLE LONG TERM DIVIDEND \"AM2\" (HKD) INC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","MEDX":"HORIZON KINETICS MEDICAL ETF","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","RXL":"ProShares Ultra Health Care","TRUH":"VanEck Healthcare TruSector ETF","PJP":"INVESCO PHARMACEUTICALS ETF","XLV":"健康照护类股ETF-SPDR","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","IYH":"iShares U.S. Healthcare ETF","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC"},"translate_title":"前景上调后，艾伯维 (ABBV) 股票可能很便宜","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RXL":0.6,"TRUH":0.6,"XLV":0.6,"MEDX":0.6,"PJP":0.6,"IXJ":0.6,"FTXH":0.6,"FHLC":0.6,"ABBV":1.5,"JDOC":0.6,"IYH":0.6,"GLAM":0.6,"PPH":0.6,"VHT":0.6,"DCF":1,"SPHQ":0.83,"AGNG":0.6},"content_text":"AbbVie has delivered a powerful run, with the stock up 201.5% over the past 5 years and recent news flow focused on new therapies, acquisitions and higher shareholder payouts. With that kind of share price record, the key issue for you is whether the current valuation is properly grounded in the cash flows the business can generate over time.  Over 5 years, AbbVie has returned 201.5%. That puts real pressure on the question of whether the cash the company can produce is keeping pace with the market's optimism. Recent deals and pipeline progress in immunology, neuroscience and migraine treatments can support expectations for future cash generation but also commit AbbVie to sizeable investment and integration work that affects when and how those cash flows arrive. Prefer to judge AbbVie on earnings? See why AbbVie's 50.4x P/E tells a different valuation story.  The issue now is whether AbbVie’s current share price can be justified by the cash flows implied by its Discounted Cash Flow (DCF) intrinsic value estimate. If you want a cleaner reference point for AbbVie’s 201.5% five year run and the focus on whether cash flows justify that kind of move, it can help to line it up against 35 high quality undervalued stocks AdvertisementDoes AbbVie Look Undervalued on Cash Flow? The Discounted Cash Flow (DCF) model here uses AbbVie’s projected free cash generation to judge what today’s price might be baking in. Latest twelve month free cash flow sits at about $18.9b, and the projections used in the model assume that this cash pool keeps growing rather than shrinking over the next decade, then settles into a more modest pace. Those cash flow estimates, once discounted back, point to an intrinsic value meaningfully above the current share price of $293.89. The strong Q3 2026 earnings update, with raised guidance and a higher dividend following the Apogee deal, helps explain why a cash flow based model can still come out ahead of where the market is pricing AbbVie today. Find out what AbbVie could be worth using our Discounted Cash Flow (DCF) estimate. The AbbVie Narrative: What Would Justify Today's Price? Simply Wall St Narratives pick up where AbbVie’s valuation puzzle leaves off. They spell out the specific growth, margin and earnings paths that would need to play out for the stock to be worth meaningfully more or less than today’s price, so you can see the future story that sits behind any single DCF output or ratio, and then watch over time whether AbbVie’s actual progress keeps matching that script. One of the top narratives on AbbVie: roughly fairly valued This Narrative is the analyst consensus Narrative on Simply Wall St, which compiles analysts' consensus price target and revenue and earnings forecasts, not one person's view. \"The key requirement for AbbVie is successfully executing on its pipeline and business development so that new immunology, oncology and neuroscience drugs replace revenue from declining products such as Humira and Imbruvica...\" Discover why this Narrative puts AbbVie at roughly fairly valued. One more AbbVie check that belongs next to the cash flow math The executives steering AbbVie, how they are rewarded, and whether those incentives line up with long term shareholder outcomes can matter as much as any DCF output. See who runs AbbVie and how they are paid. This article is general in nature and was produced with the assistance of AI automation,\n        based on data and analysis from Simply Wall St. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2682832095","isCrawlerRequest":true}